Sugi Predict

Sugi Predict / Compounds / SCHEMBL9963890

SCHEMBL9963890

SCHEMBL9963890

CC(C)(C)OC(=O)N[C@H](Cc1ccc(-c2ccccc2)cc1)C(=O)C1C(=O)OC(C)(C)OC1=O

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CTSS P25774 7/20 0.56
▸ CTSK P43235 6/20 0.56
▸ CTSB P07858 2/20 0.48
▸ CTSL P07711 1/20 0.48
▸ BCL2 P10415 1/20 0.48
▸ ACE P12821 1/20 0.47
▸ CCKAR P32238 2/20 0.46
▸ CCKBR P32239 2/20 0.46
▸ AKT1 P31749 1/20 0.46
▸ SCN9A Q15858 2/20 0.45
▸ PTPN1 P18031 1/20 0.44
▸ KLK5 Q9Y337 1/20 0.44
▸ EPHX2 P34913 1/20 0.44
▸ ITGA4 P13612 1/20 0.44
▸ ITGB7 P26010 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20734850 0.95 CTSS (0.54) CTSSCTSKCTSBCTSLACE
SCHEMBL22154195 0.95 CTSS (0.54) CTSSCTSKCTSBCTSLACE
SCHEMBL21650117 0.90 CTSK (0.50) CTSSCTSKCTSBCTSLBCL2
SCHEMBL14902381 0.90 CTSS (0.47) CTSSCTSKCTSBCTSLBCL2
SCHEMBL19696544 0.90 CTSS (0.47) CTSSCTSKCTSBCTSLBCL2
SCHEMBL18597844 0.90 CTSS (0.47) CTSSCTSKCTSBCTSLBCL2
SCHEMBL19888360 0.89 MME (0.43) CTSSCTSKACEITGA4ITGB7
SCHEMBL22154821 0.89 CTSS (0.54) CTSSCTSKCTSBCTSLACE
SCHEMBL22154820 0.89 CTSS (0.54) CTSSCTSKCTSBCTSLACE
SCHEMBL22901894 0.89 PPARG (0.45) CTSSCTSKCTSBCTSLBCL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12016835-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2024-06-25 — — US disclosed
US-20230312537-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP LLC (US) 2023-10-05 — — US disclosed
US-20230285340-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP LLC (US) 2023-09-14 — — US disclosed
US-20230285340-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP LLC (US) 2023-09-14 — — US disclosed
US-11634413-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2023-04-25 — — US disclosed
US-11547687-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2023-01-10 — — US disclosed
US-11547687-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2023-01-10 — — US disclosed
US-20220106300-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2022-04-07 — — US disclosed
US-11124502-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2021-09-21 — — US disclosed
US-20210079017-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2021-03-18 — — US disclosed
US-8449890-B2 Neprilysin inhibitors THERAVANCE, INC. (US) 2013-05-28 — — US disclosed
WO-2013067163-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2013-05-10 — — WO disclosed
US-20130109639-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC 2013-05-02 — — US disclosed
US-20130109639-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC 2013-05-02 — — US disclosed
WO-2012154249-A1 SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2012-11-15 — — WO disclosed
US-20120213807-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2012-08-23 — — US disclosed
US-20120213806-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2012-08-23 — — US disclosed
US-20120157383-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2012-06-21 — — US disclosed
US-20120157383-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2012-06-21 — — US disclosed
WO-2012082853-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2012-06-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230285340-A1 NEPRILYSIN INHIBITORS MME, REN, ACE CTSS 86/4885CTSK 123/4885CTSB 25/4885
US-20130109639-A1 NEPRILYSIN INHIBITORS MME, REN, ACE CTSS 86/4885CTSK 123/4885CTSB 25/4885
US-11547687-B2 Neprilysin inhibitors MME, REN, ACE CTSS 86/4885CTSK 123/4885CTSB 25/4885
US-20120213806-A1 NEPRILYSIN INHIBITORS MME, REN, ACE CTSS 107/4885CTSK 128/4885CTSB 35/4885
US-20120213807-A1 NEPRILYSIN INHIBITORS MME, REN, EDNRB CTSS 115/4885CTSK 139/4885CTSB 12/4885
US-20210079017-A1 NEPRILYSIN INHIBITORS MME, REN, ACE CTSS 117/4885CTSK 178/4885CTSB 32/4885
US-20220106300-A1 NEPRILYSIN INHIBITORS MME, REN, ACE CTSS 69/4885CTSK 109/4885CTSB 49/4885
US-11634413-B2 Neprilysin inhibitors MME, REN, ACE CTSS 69/4885CTSK 109/4885CTSB 49/4885
US-11124502-B2 Neprilysin inhibitors MME, REN, ACE CTSS 69/4885CTSK 109/4885CTSB 49/4885
US-20230312537-A1 NEPRILYSIN INHIBITORS MME, REN, ACE CTSS 69/4885CTSK 109/4885CTSB 49/4885
US-20120157383-A1 NEPRILYSIN INHIBITORS MME, REN, ACE CTSS 117/4885CTSK 178/4885CTSB 32/4885
US-12016835-B2 Neprilysin inhibitors MME, REN, ACE CTSS 86/4885CTSK 123/4885CTSB 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback